Moberg Pharma and Colep enters agreement for late-stage development of MOB-015
Wednesday, November 04, 2015
Moberg Pharma and Colep enters development agreement for late-stage development of MOB-015.
Moberg will own all data and documentation generated from the pharmaceutical development program and plans to initiate a clinical phase 3 program in 2016.
The parties will enter a supply agreement for a subsequent commercial phase building on synergies from other products that Colep currently manufactures for Moberg.
reuters.com
